Pfizer taps Chinese expertise for novel drugs for MDR-TB
This article was originally published in Scrip
Executive Summary
Pfizer has entered into an agreement for collaborative research with MicuRx Pharmaceuticals and MicuRx's Chinese affiliate, Cumencor Pharmaceuticals, for the development of novel therapeutics against multi-drug-resistant tuberculosis (MDR-TB).